F B Hagemeister - JoVE Visualize

Showing results (71-80 of 124) with videos related to

Pageof 13

Sort By:

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002

Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?I Barista, F Cabanillas, J E Romaguera, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1989

Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's diseaseK M Taylor, S Jagannath, G Spitzer, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 1992

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphomaJ R Redman, F Cabanillas, W S Velasquez, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 1992

Therapy of relapsed or refractory low-grade follicular lymphomas: factors associated with complete remission, survival and time to treatment failureJ A Spinolo, F Cabanillas, D O Dixon, et al.

Clinical Lymphoma|November 15, 2001

Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?C Visco, L J Medeiros, O M Mesina, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaA Younes, H A Preti, F B Hagemeister, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion scheduleA Younes, J P Ayoub, F B Hagemeister, et al.

Radiology|December 1, 1981

Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomyF B Hagemeister, L M Fuller, J A Sullivan, et al.

Leukemia & Lymphoma|April 1, 1993

A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicityJ C Liang, N M Bailey, G J Gabriel, et al.

Investigational New Drugs|January 1, 1994

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomasJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.

Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:

Pageof 13

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002

Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?I Barista, F Cabanillas, J E Romaguera, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1989

Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's diseaseK M Taylor, S Jagannath, G Spitzer, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 1992

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphomaJ R Redman, F Cabanillas, W S Velasquez, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 1992

Therapy of relapsed or refractory low-grade follicular lymphomas: factors associated with complete remission, survival and time to treatment failureJ A Spinolo, F Cabanillas, D O Dixon, et al.

Clinical Lymphoma|November 15, 2001

Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?C Visco, L J Medeiros, O M Mesina, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaA Younes, H A Preti, F B Hagemeister, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion scheduleA Younes, J P Ayoub, F B Hagemeister, et al.

Radiology|December 1, 1981

Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomyF B Hagemeister, L M Fuller, J A Sullivan, et al.

Leukemia & Lymphoma|April 1, 1993

A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicityJ C Liang, N M Bailey, G J Gabriel, et al.

Investigational New Drugs|January 1, 1994

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomasJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.

Pageof 13